Thomas Stephen Basil 4

What Happened
Thomas S. Basil, a director of Climb Bio, sold a total of 50,000 shares in two open-market transactions: 33,687 shares on 2026-02-25 for a weighted avg price of $7.00 (proceeds ~$235,964) and 16,313 shares on 2026-02-26 for a weighted avg price of $7.01 (proceeds ~$114,289). Combined proceeds were approximately $350,253. These were outright sales (S), not purchases or option exercises.

Key Details

• Transaction dates: 2026-02-25 (33,687 shares) and 2026-02-26 (16,313 shares).
• Reported prices: weighted averages $7.00 (2/25) and $7.01 (2/26). Individual sale prices ranged from $7.0000 to $7.0600 (2/25) and $7.0000 to $7.0400 (2/26).
• Total shares sold: 50,000; total proceeds: about $350,253.
• Trades executed pursuant to a Rule 10b5‑1 trading plan adopted by Mr. Basil on October 14, 2025 (pre‑arranged plan).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing: Form 4 filed 2026-02-27 reporting transactions dated 2026-02-25 — no late filing flag indicated.

Context
Sales under a Rule 10b5‑1 plan are pre-scheduled arrangements that can make insider sales routine and do not necessarily signal a change in the insider’s view of the company. For retail investors, purchases tend to be more informative than routine sales; this filing documents a planned sale that produced modest proceeds (~$350k).